Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.
Bueno-de-Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ. Bueno-de-Mesquita JM, et al. Among authors: van de vijver mj, van tinteren h. Ann Oncol. 2010 Jan;21(1):40-7. doi: 10.1093/annonc/mdp273. Epub 2009 Jul 21. Ann Oncol. 2010. PMID: 19622588 Free article.
p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ. Clahsen PC, et al. Among authors: van den broek l, van de vijver mj, van de velde cj. J Clin Oncol. 1998 Feb;16(2):470-9. doi: 10.1200/JCO.1998.16.2.470. J Clin Oncol. 1998. PMID: 9469330 Clinical Trial.
The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, van de Vijver MJ. Clahsen PC, et al. Among authors: van den broek l, van de vijver mj, van de velde cj. Eur J Surg Oncol. 1999 Aug;25(4):356-63. doi: 10.1053/ejso.1999.0657. Eur J Surg Oncol. 1999. PMID: 10419704
High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de Velde CJ, van den Broek LC, van de Vijver MJ. Elkhuizen PH, et al. Among authors: van slooten hj, van de vijver mj, van de velde cj, van den broek lc. J Clin Oncol. 2000 Mar;18(5):1075-83. doi: 10.1200/JCO.2000.18.5.1075. J Clin Oncol. 2000. PMID: 10694560 Clinical Trial.
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.
Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ. Bijker N, et al. Among authors: van de vijver mj, de mascarel i. J Clin Oncol. 2001 Apr 15;19(8):2263-71. doi: 10.1200/JCO.2001.19.8.2263. J Clin Oncol. 2001. PMID: 11304780 Clinical Trial.
314 results